MECHANISMS OF PROTECTION AGAINST RETROVIRAL INFECTIONS INDUCED WITH A SINGLE-EPITOPE CD4^+ T-CELL VACCINE

单表位 CD4^ T 细胞疫苗诱导的逆转录病毒感染的保护机制

基本信息

  • 批准号:
    11670307
  • 负责人:
  • 金额:
    $ 2.3万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1999
  • 资助国家:
    日本
  • 起止时间:
    1999 至 2000
  • 项目状态:
    已结题

项目摘要

We have previously shown that immunization with a synthetic peptide that contains a single CD4^+ T-cell epitope protects highly susceptible mice against immunosuppressive Friend retrovirus infection. Cells producing infectious Friend virus were rapidly eliminated from the spleen of mice that had been immunized with the single- epitope peptide. However, actual effector mechanisms induced through T-helper cell responses after Friend virus inoculation were unknown. When cytotoxic effector cells detected in the early phase of Friend retrovirus infection were separated based on their expression of cell surface markers, those lacking CD4 and CD8 but expressing natural killer cell markers were found to constitute the majority of effector cells that lysed Friend virus-induced leukemia cells. Depletion of natural killer cells by injecting anti-asialo GM_1 antibody did not affect the number of CD4^+ or CD8^+ T cells in the spleen, virus antigen-specific proliferative responses of CD4^+ T cells, … More or cytotoxic activity against Friend virus-induced leukemia cells exerted by CD8^+ effector cells, but completely abolished the effect of peptide immunization. Although the above enhancement of natural killer cell activity in the early stage of Friend virus infection was also observed in mice given no peptide, these results have demonstrated the importance and requirement of natural killer cells in the vaccine-induced resistance against the retroviral infection.Other sets of cell-depletion and transfer experiments also showed that CD4^+ and CD8^+ T cells were required for the vaccine-induced protection against Friend retrovirus infection, and the presence of CD4^+ T cells was absolutely required for the production, but not just class switching, of virus-neutralizing antibodies. Thus, these results clearly show that a single-epitope CD4^+ T cell vaccine induces immune resistance against Friend retrovirus infection by rapidly activating multiple effector mechanism soon after the virus infection including CD4^+ and CD8^+ cytotoxic effector cells, virus-neutralizing antibodies, and NK cells. Less
我们之前已经证明,用含有单个 CD4^+ T 细胞表位的合成肽进行免疫可以保护高度易感的小鼠免受免疫抑制性 Friend 逆转录病毒感染。产生传染性弗兰德病毒的细胞被迅速从用单表位肽免疫的小鼠的脾脏中消除。然而,接种弗兰德病毒后通过 T 辅助细胞反应诱导的实际效应机制尚不清楚。当根据细胞表面标志物的表达来分离弗兰德逆转录病毒感染早期检测到的细胞毒性效应细胞时,发现那些缺乏CD4和CD8但表达自然杀伤细胞标志物的细胞构成了裂解弗兰德病毒诱导的白血病细胞的大部分效应细胞。通过注射抗asialo GM_1抗体来消除自然杀伤细胞,并不会影响脾脏中CD4^+或CD8^+ T细胞的数量、CD4^+ T细胞的病毒抗原特异性增殖反应,或CD8^+效应细胞对Friend病毒诱导的白血病细胞发挥的细胞毒活性,但完全消除了肽免疫的效果。尽管在未给予肽的小鼠中也观察到上述在Friend病毒感染早期自然杀伤细胞活性的增强,但这些结果证明了自然杀伤细胞在疫苗诱导的针对逆转录病毒感染的抵抗力中的重要性和必要性。其他组的细胞耗竭和转移实验也表明CD4^+和CD8^+T细胞是疫苗诱导的针对Friend逆转录病毒感染的保护所必需的, CD4^+ T 细胞的存在对于病毒中和抗体的产生(而不仅仅是类别转换)是绝对必需的。因此,这些结果清楚地表明,单表位 CD4^+ T 细胞疫苗通过在病毒感染后迅速激活多种效应机制(包括 CD4^+ 和 CD8^+ 细胞毒性效应细胞、病毒中和抗体和 NK 细胞),诱导针对 Friend 逆转录病毒感染的免疫抵抗。较少的

项目成果

期刊论文数量(23)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Iwanami, N, et al.: "Role of natural killer cells in resistance against Friend retrovirus-induced leukemia."Journal of Virology. 75(in press). (2001)
Iwanami, N 等人:“自然杀伤细胞在抵抗 Friend 逆转录病毒诱导的白血病中的作用。”病毒学杂志。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Keiji Hashimoto: "Induction of microthrombotic thrombocytopenia in normal mice by transferring a platelet-reactive,monoclonal anti-gp70 autoantibody"Clin.Exp.Immunol.. 119. 47-56 (2000)
Keiji Hashimoto:“通过转移血小板反应性单克隆抗 gp70 自身抗体在正常小鼠中诱导微血栓性血小板减少症”Clin.Exp.Immunol.. 119. 47-56 (2000)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Miyazawa, M., et al.: "Squirrel monkey retrovirus (SMRV) sequence from an SMRV-negative cell line?"Journal of Hepatology. 31. 967-968 (1999)
Miyazawa, M., et al.:“来自 SMRV 阴性细胞系的松鼠猴逆转录病毒 (SMRV) 序列?”肝脏病学杂志。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MIYAZAWA Masaaki其他文献

MIYAZAWA Masaaki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MIYAZAWA Masaaki', 18)}}的其他基金

Designing novel protease inhibitors based on the interference of mouse APOBEC3 with retroviral Gag-Pol autocatalysis
基于小鼠 APOBEC3 干扰逆转录病毒 Gag-Pol 自催化设计新型蛋白酶抑制剂
  • 批准号:
    16H05199
  • 财政年份:
    2016
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mechanisms of regulation of host immune responses by retrovirus-restricting enzyme APOBEC3
逆转录病毒限制酶 APOBEC3 调节宿主免疫反应的机制
  • 批准号:
    24390116
  • 财政年份:
    2012
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Regulation of APOBEC3 gene expression and its transcript splicing
APOBEC3基因表达及其转录剪接的调控
  • 批准号:
    21390143
  • 财政年份:
    2009
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Analyses of host genes that confer immune resistance against human immunodeficiency virus type-1 infection in HIV-1-exposed but uninfected individuals in the overseas cohorts
海外队列中 HIV-1 暴露但未感染个体对人类免疫缺陷病毒 1 型感染具有免疫抵抗力的宿主基因分析
  • 批准号:
    15406021
  • 财政年份:
    2003
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Structural analysis of protective and non-protective T-cell epitopes encoded with in the retroviral gag gene product
逆转录病毒 gag 基因产物编码的保护性和非保护性 T 细胞表位的结构分析
  • 批准号:
    13670305
  • 财政年份:
    2001
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of tissue injury induced with anti-gp70 autoantibodies
抗gp70自身抗体诱导组织损伤的机制
  • 批准号:
    07670230
  • 财政年份:
    1995
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

新生期接种乙肝疫苗(hepatitis B vaccine,HBV)影响小鼠情绪相关行为及其机制研究
  • 批准号:
    31600836
  • 批准年份:
    2016
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Development of a Cell-Based Assay for Tetanus Vaccine Quality Control
破伤风疫苗质量控制细胞检测方法的开发
  • 批准号:
    10101986
  • 财政年份:
    2024
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Collaborative R&D
Developing an infection-blocking pan-coronavirus vaccine
开发阻断感染的泛冠状病毒疫苗
  • 批准号:
    MR/Y019466/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Research Grant
Vaccine hesitancy DAISI (Digital Animation in Service Improvement): To increase vaccine uptake in ethnic minority perinatal women and young children.
疫苗犹豫 DAISI(服务改进中的数字动画):提高少数民族围产期妇女和幼儿的疫苗接种率。
  • 批准号:
    MR/Z503964/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Research Grant
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Research Grant
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Standard Grant
Evolutionarily smart vaccine strain selection for proactive vaccinology
用于主动疫苗学的进化智能疫苗株选择
  • 批准号:
    MR/Y004337/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Research Grant
Development of a mucosally-delivered and active salmon louse vaccine for Atlantic salmon aquaculture
开发用于大西洋鲑鱼水产养殖的粘膜递送活性鲑鱼虱疫苗
  • 批准号:
    BB/Y006534/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Research Grant
Application of the virus-like particle (VLP) technology in the development of anti-tick vaccine, utilizing novel salivary proteins from Haemaphysalis longicornis ticks.
利用长角血蜱的新型唾液蛋白,应用病毒样颗粒(VLP)技术开发抗蜱疫苗。
  • 批准号:
    24K18027
  • 财政年份:
    2024
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A novel self-adjuvanting vaccine platform
一种新型的自我辅助疫苗平台
  • 批准号:
    MR/Z503885/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Research Grant
Developing bovine immune organoids for the screening of vaccine candidates
开发牛免疫类器官用于筛选候选疫苗
  • 批准号:
    NC/Y000889/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了